ProShare Advisors’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-5,855
| Closed | -$597K | – | 1878 |
|
|
2023
Q2 | $597K | Buy |
5,855
+376
| +7% | +$38.3K | ﹤0.01% | 876 |
|
|
2023
Q1 | $498K | Sell |
5,479
-703
| -11% | -$63.9K | ﹤0.01% | 913 |
|
|
2022
Q4 | $235K | Buy |
+6,182
| New | +$235K | ﹤0.01% | 1382 |
|
|
2022
Q2 | – | Sell |
-8,407
| Closed | -$276K | – | 2216 |
|
|
2022
Q1 | $276K | Sell |
8,407
-2,021
| -19% | -$66.3K | ﹤0.01% | 1685 |
|
|
2021
Q4 | $275K | Buy |
10,428
+190
| +2% | +$5.01K | ﹤0.01% | 1840 |
|
|
2021
Q3 | $1.03M | Sell |
10,238
-2,521
| -20% | -$254K | ﹤0.01% | 899 |
|
|
2021
Q2 | $1.81M | Buy |
12,759
+8,468
| +197% | +$1.2M | 0.01% | 759 |
|
|
2021
Q1 | $428K | Sell |
4,291
-160
| -4% | -$16K | ﹤0.01% | 1541 |
|
|
2020
Q4 | $550K | Sell |
4,451
-151
| -3% | -$18.7K | ﹤0.01% | 1208 |
|
|
2020
Q3 | $448K | Buy |
4,602
+102
| +2% | +$9.93K | ﹤0.01% | 989 |
|
|
2020
Q2 | $702K | Sell |
4,500
-616
| -12% | -$96.1K | ﹤0.01% | 811 |
|
|
2020
Q1 | $738K | Sell |
5,116
-3,872
| -43% | -$559K | 0.01% | 657 |
|
|
2019
Q4 | $1.84M | Buy |
8,988
+71
| +0.8% | +$14.5K | 0.01% | 637 |
|
|
2019
Q3 | $716K | Sell |
8,917
-213
| -2% | -$17.1K | ﹤0.01% | 863 |
|
|
2019
Q2 | $861K | Sell |
9,130
-1,104
| -11% | -$104K | 0.01% | 813 |
|
|
2019
Q1 | $875K | Buy |
10,234
+133
| +1% | +$11.4K | 0.01% | 821 |
|
|
2018
Q4 | $567K | Sell |
10,101
-1,863
| -16% | -$105K | ﹤0.01% | 904 |
|
|
2018
Q3 | $978K | Buy |
11,964
+1,388
| +13% | +$113K | 0.01% | 825 |
|
|
2018
Q2 | $370K | Sell |
10,576
-45
| -0.4% | -$1.57K | ﹤0.01% | 1264 |
|
|
2018
Q1 | $218K | Sell |
10,621
-1,749
| -14% | -$35.9K | ﹤0.01% | 1512 |
|
|
2017
Q4 | $350K | Buy |
+12,370
| New | +$350K | ﹤0.01% | 1300 |
|